These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 10623754)
41. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Charles PC; Brown KW; Davis NL; Hart MK; Johnston RE Virology; 1997 Feb; 228(2):153-60. PubMed ID: 9123821 [TBL] [Abstract][Full Text] [Related]
42. Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein. Johnson BJ; Brubaker JR; Roehrig JT; Trent DW Virology; 1990 Aug; 177(2):676-83. PubMed ID: 1695412 [TBL] [Abstract][Full Text] [Related]
43. Venezuelan equine encephalitis virus in the mosquito vector Aedes taeniorhynchus: infection initiated by a small number of susceptible epithelial cells and a population bottleneck. Smith DR; Adams AP; Kenney JL; Wang E; Weaver SC Virology; 2008 Mar; 372(1):176-86. PubMed ID: 18023837 [TBL] [Abstract][Full Text] [Related]
44. [The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus]. Sviatchenko VA; Agapov EV; Urmanov IKh; Serpinskiĭ OI; Frolov IV; Kolykhalov AA; Ryzhikov AB; Netesov SV Vopr Virusol; 1993; 38(5):222-6. PubMed ID: 8284922 [TBL] [Abstract][Full Text] [Related]
45. [Laminin-binding protein (LBP) as a cellular receptor for the virus of Venezuelan equine encephalomyelitis (VEE): Part 1. A study of the interaction between VEE virus virions and the human recombinant LBP]. Bondarenko EI; Protopopova EV; Konovalova SN; Sorokin AV; Kachko AV; Surovtsev IV; Loktev VB Mol Gen Mikrobiol Virusol; 2003; (4):36-9. PubMed ID: 14664162 [TBL] [Abstract][Full Text] [Related]
46. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. Perri S; Greer CE; Thudium K; Doe B; Legg H; Liu H; Romero RE; Tang Z; Bin Q; Dubensky TW; Vajdy M; Otten GR; Polo JM J Virol; 2003 Oct; 77(19):10394-403. PubMed ID: 12970424 [TBL] [Abstract][Full Text] [Related]
47. Equine amplification and virulence of subtype IE Venezuelan equine encephalitis viruses isolated during the 1993 and 1996 Mexican epizootics. Gonzalez-Salazar D; Estrada-Franco JG; Carrara AS; Aronson JF; Weaver SC Emerg Infect Dis; 2003 Feb; 9(2):161-8. PubMed ID: 12603985 [TBL] [Abstract][Full Text] [Related]
48. Association of Tonate virus (subtype IIIB of the Venezuelan equine encephalitis complex) with encephalitis in a human. Hommel D; Heraud JM; Hulin A; Talarmin A Clin Infect Dis; 2000 Jan; 30(1):188-90. PubMed ID: 10619752 [TBL] [Abstract][Full Text] [Related]
49. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Bernard KA; Klimstra WB; Johnston RE Virology; 2000 Oct; 276(1):93-103. PubMed ID: 11021998 [TBL] [Abstract][Full Text] [Related]
50. Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. Kamrud KI; Alterson KD; Andrews C; Copp LO; Lewis WC; Hubby B; Patel D; Rayner JO; Talarico T; Smith JF PLoS One; 2008 Jul; 3(7):e2709. PubMed ID: 18628938 [TBL] [Abstract][Full Text] [Related]
51. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Davis NL; Powell N; Greenwald GF; Willis LV; Johnson BJ; Smith JF; Johnston RE Virology; 1991 Jul; 183(1):20-31. PubMed ID: 2053280 [TBL] [Abstract][Full Text] [Related]
52. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002 [TBL] [Abstract][Full Text] [Related]